In this study, we show that high serum levels of soluble human leukocyte antigens (HLA) class I molecules (sHLA-I, range: 0.7-1.7 lg/ml) and soluble Fas ligand (FasL, range: 0.4-1.9 ng/ml) are detected in patients with acute myeloid leukemia (AML) at diagnosis, compared with healthy donors (HD) (sHLA-I, range: 0.1-0.6 lg/ml; sFasL, range: 0.1-0.4 ng/ml). Patients' sera were able to induce transcription and secretion of FasL in CD8 þ T cells, followed by apoptosis in vitro; this apoptosis was inhibited by anti-HLA-I-specific monoclonal antibodies, suggesting that sHLA-I is responsible for cell death. These findings closely relate to the in vivo upregulation of FasL transcription observed in peripheral blood (PB) lymphocytes from AML patients; in the same cells, mRNA for the antiapoptotic proteins Bcl-2 and Bcl-x L was downregulated. Interestingly, caspase-8 and caspase-3, both downstream mediators of death receptorinduced apoptosis, were activated in CD8 þ cells of AML patients; one-third of these cells were already apoptotic in vivo, at variance with lymphocytes of HD. These data strongly suggest that in AML, increased levels of sHLA-I molecules may contribute to the elimination of potentially anti-tumor effector cells through a FasL/Fas interaction.
Introduction
The major histocompatibility complex class I products (human leukocyte antigens (HLA)-I) are heterodimers composed of a heavy a chain of 44 kDa and a b2-microglobulin light chain. 1, 2 Beside being expressed on most nucleated cells, both b2-microglobulin associated and free HLA-I heavy chains have been detected in serum. [2] [3] [4] [5] More recently, it has been shown that the serum level of these soluble molecules is significantly increased in patients with an activation of their immune system, such as during allograft rejection, autoimmune diseases or viral infections. 1, 6 Because of the statistical significant association with clinical parameters, the amount of soluble human leukocyte antigens (sHLA)-I antigens has been proposed as a useful marker to predict the evolution of chronic viral infections and the clinical course of allografts. 1, [6] [7] [8] [9] Moreover, sHLA-I molecules can be released by tumor cells, and high sHLA-I serum levels have been found in solid cancers, melanomas and lymphomas. [10] [11] [12] [13] Thus, sHLA-I molecule are not specific markers for organ rejection, but rather are affected by inflammatory processes and viral or neoplastic transformation.
The functional role of sHLA-I molecules either in physiological or in pathological conditions is not clear: it has been described that HLA-I molecules can trigger cytotoxic T lymphocytes to release cytolitic enzymes and proinflammatory cytokines.
14-16 However, we and others reported that sHLA-I molecules lead to activation-induced apoptosis, in vitro, mediated by synthesis and secretion of FasL and the consequent interaction with Fas expressed by allogeneic and autologous T and natural killer (NK) cells. [17] [18] [19] [20] [21] Furthermore, nanomolar concentrations of sHLA-I can prevent both alloreactive clones and primary T-cell cultures from recognizing and lysing their targets. 20 It has been reported that sHLA-I molecules bind to CD8 receptors expressed on cytotoxic effector lymphocytes, that is T and NK cells. 18, 22, 23 Thus, sHLA-I-induced apoptosis could represent a mechanism of downregulation of NK-and T-lymphocyte-mediated functions that ultimately limit selfreaction. However, the same mechanism might allow tumor cells to evade the immune surveillance exerted by T or NK cells.
In this paper, we show that (i) high levels of sHLA-I are detected in the serum of patients with acute myeloid leukemias (AML) at diagnosis; (ii) these amounts increase during chemotherapy, but fall to normal levels upon post-chemotherapy remission; (iii) sHLA-I increase is paralleled by the rise in serum sFasL and by the upregulation of FasL transcription in PB lymphocytes of these patients; (iv) in the same patients, Bcl-2 and Bcl-x L are downregulated and caspase-8 and caspase-3 are activated in CD8 þ cells that are committed to apoptosis in vivo. 18, 19 The amount of sHLA-I was referred to a standard curve performed with serial dilution of known amounts of sHLA-I molecules obtained from serum of healthy subjects by affinity chromatography, as described. 18, 19 Then, streptavidin conjugated with horseradish peroxidase (HRP) (Pierce, Rockford, IL, USA) was added for 1 h at room temperature (RT) and the reaction developed for 15 min at RT in the dark with o-phenylenediamine. Optical density (OD) was read with a spectrophotometer at 490 nm against blank (phosphate-buffered saline/bovine serum albumin 5%). Soluble FasL (sFasL) was measured in AML or HD sera or in the supernatants (SN) harvested from CD8 þ cells incubated with AML or HD sera (incubation of 6 h, followed by extensive washing and culture for further 24 h) by ELISA with anti-FasL mAb NOK-2 (capture antibody) incubated for 45 min at RT, followed by biotinconjugated anti-FasL mAb NOK-1 (detection antibody) for additional 45 min at RT. Streptavidin-HRP was then added and samples were treated and developed as indicated above. Standard curve was obtained using progressive dilution of recombinant FasL from Alexis Co. (Leufelfingen, Switzerland). Soluble CD8 (sCD8) was evaluated by ELISA (Peprotec, London, UK) and referred to the standard curve. Lactate dehydrogenase (LDH) serum concentration was measured by spectrophotometric analysis. Results were expressed in mg/ml for sHLA-I, ng/ml for sFasL, U/ml for sCD8 and U/l for LDH, and are the mean7s.d. of triplicate wells.
Materials and methods

Patients and therapy
mRNA isolation, reverse transcription and polymerase chain reaction amplification for FasL, Bcl-2 and Bcl-x L Total RNA was isolated from pellets of lymphocytes isolated from PB by negative depletion, with the RosetteSep for T and NK cell enrichment (StemCell Technologies, Vancouver, BC, Canada) to get rid of monocytes and neoplastic cells, by using the RNAzol B method (Biotecx Laboratories Inc., Huston, TX, USA). Complementary DNA (cDNA) (corresponding to 2 mg of RNA) was synthesized from oligo(dT)-primed RNA in 20 ml reverse transcriptase buffer and 200 U Moloney murine leukemia virus reverse transcriptase (Perkin Elmer-Cetus, Boston, MA, USA) and incubated at 421C for 45 min and 521C for 45 min. FasL, b-actin, GAPDH, Bcl-x L and Bcl-2 were amplified with 2.5 U Amply Taq Gold Polymerase (Perkin Elmer-Cetus, Monza, Milan, Italy) in 2 mM dNTP, 50 mM 5 0 and 3 0 oligonucleotide primers containing 2.5 mM, 5 mM and 1 mM MgCl 2 , respectively. The sequence (5 0 -3 0 ) of the specific primers used and amplification conditions have been previously reported. 18, 24 An extension of all products was performed for 7 min at 721C at the end of the last cycle and then the products were held at 41C.
Polymerase chain reaction (PCR) products were size-fractionated by agarose gel electrophoresis stained with ethidium bromide and normalized according to the amount of b-actin or GAPDH detected in the same mRNA sample. 18, 24 Briefly, images were acquired by Chemi 550 (AlphaInnotech, San Leonardo, CA, USA) and analyzed by a Gel Pro Analyzer 3.1 (Media Cybernetics, Silver Spring, MD, USA). Results of the densitometric analysis, measured as pixel number Â 10
À3
arbitrary units, were expressed as FasL/b-actin ratio, or Bcl-2/ GAPDH or Bcl-x L /GAPDH ratio.
Induction and detection of apoptosis
Polyclonal CD8
þ T cells (10 5 /ml), obtained as described, 23 were cultured in 24-well flat-bottomed plates (Becton Dickinson, Oxnard, CA, USA) in the presence of patients' or HD serum (1:2 dilution), in the absence or presence of anti-HLA-I mAb (W6/32, 5 mg/ml) or anti-FasL mAb (Alf-2, Ancell Corporation, Bayport, MN, USA; 5 mg/ml), or with sHLA-I (kind gift from S Ferrone, Roswell Park Memorial, Buffalo, NY, USA; 2 or 1 mg/ml) 
18,19
Detection of activated caspase-8 and caspase-3 in situ
The activation of caspase-8 and caspase-3 was evaluated in PBL of HD and AML patients before and after chemotherapy, using the Caspase-8 and Caspase-3 Detection Kit (Calbiochem, Darmstadt, Germany). The assay utilizes IETD-fluoromethyl ketone (-FMK) or DEVD-FMK conjugated to fluoresceinisothiocyanate (FITC) as caspase-8 or caspase-3 in situ marker. FITC-IETD-FMK and FITC-DEVD-FMK are cell permeable, non-toxic and irreversibly bind only to activated caspase-8 or caspase-3 in apoptotic cells. To identify CD8 þ effector lymphocytes, T or NK cells, the PE-anti-CD8, anti-CD3 and anti-CD16 mAbs from BD Pharmingen Europe (Milan, Italy) were used. Samples were run on a flow cytometer (FACSort, BectonDickinson, Milan, Italy) equipped with an argon ion laser. Data were analyzed using the CellQuest computer program and are expressed as Log red fluorescence intensity (arbitrary units (a.u.)) vs Log green fluorescence intensity (a.u.).
Statistical analysis
Statistical analysis was performed using Student's t-test.
Results
sHLA-I and sFasL are increased in the serum of AML patients sHLA-I levels were found to be higher in the sera obtained from AML patients at diagnosis (range: 0. 7-1.9 mg/ml; Figure 1a ) than in healthy donors (HD, range: 0.1-0.6 mg/ml; Figure 1a) . When evaluated at different time points after chemotherapy, an increase in serum sHLA-I levels (DsHLA-I) of 0.4-0.6 mg/ml was found, starting from day 1 up to day 5, compared with the amounts detected at diagnosis ( Figure 1b) ; sHLA-I serum concentration turned back to pre-chemotherapy levels by day 9 (Figure 1b) . On the other hand, high amounts of LDH (4500 U/l) were detected on day 1 and then decreased starting from day 3 to reach normal levels (o200 U/ml) during the following days (Figure 1c) . sFasL was also measured in HD and AML patients, before and during chemotherapy as above, and results are expressed as ng/ml at diagnosis or as ng/ml of increase (DsFasL) on days 1, 3, 5, 7 and 9 of therapy. Again, we found higher amounts of sFasL in AML sera (range: 0.4-1.9 ng/ ml) than in HD (range: 0.1-0.4 ng/ml; Figure 1d ), and these amounts rose after chemotherapy, with a peak on days 5-7 ( Figure 1 sHLA-I and sFasL are increased in the sera of AML patients. sHLA-I was measured by ELISA in the sera obtained from 20 AML patients before chemotherapy, and 12 HD (a), referred to a standard curve performed with purified sHLA-I molecules, and at the indicated time points after chemotherapy (b), compared with LDH (c). sFasL was measured in HD and AML patients before (d) and during chemotherapy (e), as above, by ELISA, and referred to a standard curve obtained using recombinant FasL. sCD8 was measured by ELISA (f) using the commercial kit and referred to the standard curve. Results were expressed as mg/ml for sHLA-I, ng/ml for sFasL, U/L for LDH and U/ml for sCD8. (Figure 1f , rectangle). These data would suggest that in AML patients the increases in sFasL were due to the interaction of sHLA-I with CD8 in CD8 þ cells; this interaction might be impaired in the presence of sCD8 molecules that can compete with surface CD8 for the binding of sHLA-I.
Apoptosis of CD8
sHLA-I present in the serum of AML patients induces FasL production and FasL-mediated apoptosis of CD8 þ cells
To determine whether sHLA-I molecules contained in the sera of AML patients were biologically active, CD8 þ T-cell lines were incubated with the serum, collected before therapy, of patients 02, 05, 08, 09, 12, 14, 16 and 20 with sHLA-I content of 0.9, 0.9, 1.0, 1.1, 1.2, 1.2, 1.4 and 1.9 mg/ml, respectively (1:2 diluted), washed and cultured for additional 12, 24 14-15 vs 1) . Densitometric analysis showed that the induction of FasL mRNA achieved after incubation with AML patients' sera (n ¼ 8), with sHLA-I content ranging between 0.9 and 1.9 mg/ml, was superimposable to that induced by purified sHLA-I (2 mg/ml) (Figure 2b ). The sera of four patients with the highest level of sHLA-I, indicated with a circle in Figure 2b (Pt. a), or of the two patients with low content of sHLA-I, indicated with a rectangle (Pt. b) in Figure 2b , have been titrated and added to CD8 þ cells to determine the threshold needed to induce FasL transcription. As shown in Figure 2c , no FasL mRNA upregulation was observed at dilutions lower than 1:4, that is, o0.5 mg/ml of sHLA.I, the amount usually found in HD (see 
þ cells in AML P Contini et al Figure 1a) .; this would imply that no additional soluble factors present in patients' sera are involved in FasL transcription. Transcription is followed by secretion of FasL: indeed, sFasL ranging between 4 and 6 ng/ml was detected in the SN of CD8 þ lymphocytes pre-incubated with patients sera; secretion was inhibited using saturating amounts (5 mg/ml) of the anti-HLA-I mAb, but not with murine Ig (Figure 2d ). On the other hand, HD sera (sHLA-I content of 0.1-0.6 mg/ml) did not have any effect (Figure 2d ). More importantly, patients' sera were able to induce apoptosis of CD8 þ cells after 48 h, and this effect could be blocked by either anti-HLA-I or anti-FasL mAbs (Figure 2e ). On the other hand, little or no apoptosis (o10%), measured by PI staining, was found at 24 h (not shown). These results would indicate that sHLA-I molecules contained in AML patients' sera can stimulate in CD8 þ cells transcription and secretion of FasL, which in turn, causes lymphocyte apoptosis.
Transcription of FasL is enhanced, whereas Bcl-2 or Bcl-x L is downregulated in PBL from AML In order to verify the in vivo relevance of our findings, FasL transcription was evaluated also in PBL isolated from AML patients (n ¼ 12; patients with sHLA-I ranging between 0.9 and 1.6 mg/ml) and HD (n ¼ 8, sHLA-I range 0.1-0.6 mg/ml). Figure 3a shows six representative patients and four HD. In all patients analyzed, FasL mRNA was already expressed in ex vivoisolated PBL (Figure 3a, lanes 2-7) ; densitometric analysis showed that FasL expression in AML PBL was more than 10-fold higher than in HD (FasL/b-actin ratio 1.070.03 vs 0.0770.01, Po0.01, mean7s.d. from 12 patients and eight HD, respectively). As activation of the FasL/Fas pathway is reported to activate a cascade of biochemical events leading to a shift from survival to death, and to a downregulation of antiapoptotic mechanisms, transcription of mRNA for the antiapoptotic proteins Bcl-2 and Bcl-x L 25 was evaluated in peripheral blood mononuclear cells (PBMC) isolated from the same AML patients and HD. Interestingly, expression of both Bcl-2 ( Figure 3b ) and Bcl-x L (Figure 3c 
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In vivo activation of caspase-8 and caspase-3 and apoptosis of CD8 þ cells in AML patients
The results reported above suggest that in AML patients, synthesis and secretion of FasL induced by sHLA-I can drive circulating cells to apoptosis. In order to verify this hypothesis, the activation of caspase-8 and caspase-3, as markers for FasL/Fas-mediated apoptosis, 26, 27 was evaluated in ex vivo isolated PBL of AML patients (n ¼ 12). CD8 þ effector lymphocytes, T or NK cells were identified with PE-anti-CD8, anti-CD3 and anti-CD16 mAbs. As shown in Figure 4 (one representative AML patient and one representative HD), both caspase-8 (panel a) and caspase-3 (panel b) were activated in the majority of CD8 þ cells (more than 70%, see also Table 2 ) and in almost all CD16 þ cells (which comprise the majority of NK cells) from AML patients (lower dot plots), at variance with HD (upper dot plots and Table 2 ); among CD3 þ T lymphocytes, two-third's displayed activated caspase-8 or caspase-3 in AML patients (vs o10% in HD). Of note, in the two patients with low serum sHLA-I levels, indicated in Figure 1 , no CD8 þ cells showed activation of either caspase-3 or caspase-8 (not shown).
To confirm that CD8 þ cells were actually committed to apoptosis in vivo, DNA fragmentation was analyzed in purified CD8 þ or CD4 þ cells. Figure 5 shows that in AML patients, up to one-third (from 20 to 30%) of CD8
þ , but not CD4 þ , cells were already apoptotic in vivo, as shown by PI staining (panel a: arrows, DNAo2n) or DNA laddering after agarose gel fractionation (panel b). On the contrary, no apoptotic cells were found in HD (not shown). During chemotherapy, the number of CD8 þ cells with activated caspase-8 or caspase-3 increased up to 90% on day 3; this number (Table 2) decreased to o50% on day 14 (10 days after the end of chemotherapy) and reached low levels (o15%), almost comparable to those of HD (o10%, compare Table 2 with Figure 4 ) on day 21 (about 2 weeks from the end of chemotherapy). Interestingly, the decrease of CD8 þ cells containing activated caspases closely related to the decrease of sHLA-I detectable in patients' serum ( Table 2) .
Discussion
In this paper, we show that caspase-8 and caspase-3 are activated and Bcl-2 or Bcl-x L downregulated in CD8 þ cells of AML patients at diagnosis; moreover, one-third of these cells are already apoptotic in vivo. This is strictly related to serum levels of sHLA-I and sFasL and to the upregulation of FasL transcription in PB lymphocytes of these patients.
That sHLA-I molecules are increased in the serum of patients suffering from chronic inflammatory and autoimmune diseases is well known. 1, 6 Moreover, it has become evident that sHLA-I molecules can be released by solid tumors, and high sHLA-I serum levels have been found in patients with gastric or pancreatic cancer, melanomas and lymphomas. [10] [11] [12] [13] Along this line, our findings show that also in AML, a release of sHLA-I from leukemic cells can occur in vivo. The hypothesis that sHLA-I molecules can modulate immune cell function has been proposed first in the field of allotransplants, where a tolerogenic effect of sHLA-I, owing to downregulation of T-cell functions, was described. 28 Then, a role for sHLA-I molecules in inhibiting T-and NK-cell function has been postulated in lung, breast or ovarian cancers, beside colon carcinomas, melanomas and gliomas. [29] [30] [31] In keeping with this, we and others reported that sHLA-I leads to activation-induced apoptosis through the upregulation of FasL synthesis and secretion and the consequent interaction with Fas expressed by T and NK cells. [18] [19] [20] This mechanism is apparently operating in vivo in AML patients: indeed, we found that FasL þ cells (lanes 6-9) from the same four AML patients was subjected to agarose gel electrophoresis. Lane 1: DNA markers as MW.
Apoptosis of CD8
þ cells in AML P Contini et al transcription is enhanced in lymphocytes from patients with high levels of sHLA-I. Interestingly, the serum of these patients was able to induce synthesis and secretion of sFasL, when added to CD8 þ cells in vitro, leading to their apoptosis: this phenomenon was inhibited by anti-HLA-I or anti-sFasL mAbs, confirming that the biological effect (apoptosis) was conceivably due to sHLA-I-mediated FasL production and dependent on FasL/Fas interaction.
Fas is a typical death domain-containing receptor and is the best studied member of death receptors that activate the extrinsic apoptotic pathway. 26 This pathway is triggered by the recruitment of pro-caspase-8 and its auto-activation, followed by cleavage of downstream effector caspases, such as caspase-3, whereas the intrinsic pathway starts from the release of mitochondrial proapoptotic factors that activate caspase-9. 26, 27 On the other hand, overexpression of antiapoptotic proteins, such as Bcl-2, confers cell resistance to death-receptor-induced apoptosis. 32 Expression of Bcl-2 and Bcl-x L genes in AML has been found to correlate with chemoresistance of non-proliferating leukemic cells; 33, 34 on the other hand, in some cases, low Bcl-2 expression has been found in PB cells of AML patients showing poor prognosis. 33 Here, we propose that reduced levels of Bcl-2 and related antiapoptotic proteins in CD8 þ lymphocytes of AML patients might contribute in impairing the survival and function of cytotoxic lymphocytes, possibly interfering with antitumor surveillance.
It is of note that in AML patients, at variance with HD, both caspase-8 and caspase-3 were activated in vivo in CD8 þ lymphocytes; in this regard, it has to be noted that CD8 has been reported as the major receptor responsible for the delivery of sHLA-I signal. 1, 6, 18, 23 In addition, the two caspases were found activated in almost all CD16 þ cells and more than half CD3 þ lymphocytes, These data would indicate that in these patients high levels of sHLA-I and/or sFasL trigger the death receptormediated apoptotic pathway, eventually leading to the elimination of CD8 þ cytotoxic effector cells. The finding that, in the same patients, the antiapoptotic proteins Bcl-2 and Bcl-x L are downregulated, further supports this hypothesis. More, importantly, one-third of CD8
þ , but not CD4 þ , lymphocytes are apoptotic in vivo in AML patients, as documented by DNA fragmentation: this was not found in HD (this work) nor in patients with chronic B-cell leukemias (not shown), both having low or undetectable levels of sHLA-I and sFasL in their serum.
Another point is the possible enhancement of this mechanism during chemotherapy, conceivably owing to the effect of antileukemic drugs: although activation of apoptosis via death receptors is indeed one of the most important and efficient antitumor mechanism, the same mechanism might function as a double-edged sword, allowing tumor cells to evade the immune surveillance exerted by T or NK cells. This might be particularly relevant either at the onset of the disease and/or in case of tumor cells resistant to chemotherapy that will be free to grow again in the absence of immune surveillance. We have previously reported that cyclosporin A can prevent NK cell apoptosis mediated by sHLA-I molecules. 19 It is of interest that cyclosporin A has been used in the treatment of chemoresistant or relapsed AML, owing to its inhibitory effect on multidrug resistance (MDR) proteins. [35] [36] [37] Thus, it is tempting to propose the use of this drug, not only to counteract MDR, but also to protect immune effector cells from sHLA-I-induced apoptosis, thus preventing tumor escape.
